Peptides
BPC-157
Also called Body Protection Compound
People look into BPC-157 to get past tendon or ligament injuries, improve muscle recovery, or settle persistent gut symptoms. Faster healing and less discomfort are the hoped-for benefits; they are not yet reliably established in people.
Dosage & duration
Injected under the skin; oral products have separate dosing.
House of Gaia clinic example
Reported use · unapproved regimen- Dose
- 250–500 mcg total per day
- How often
- Daily
- How long
- 4–6 weeks on, then 4 weeks off
Other sources describe different amounts and courses; this brochure is not an established medical regimen.
Sources: 3
Why people look into it
The recovery appeal
-
Tendons and ligaments
Persistent pain or injuries that limit movement.
-
Muscle recovery
Recovering from strains, rather than building extra muscle.
-
Gut symptoms
Reflux, bloating and bowel discomfort, often discussed with oral products.
Could BPC-157 help a stubborn injury?
That is its main recovery appeal: less pain and a faster return to movement. Rat studies have reported improved tendon, ligament and muscle repair. A small human knee-pain report also found symptom improvement in some people, but did not confirm that tears or cartilage had healed.
Pain relief, tissue repair and readiness to train are separate outcomes. BPC-157 has not been shown to replace an injury-specific rehabilitation plan or shorten it by a predictable number of days.
What about gut problems?
People discuss oral BPC-157 for reflux, bloating and bowel symptoms. Those symptoms can have different causes; “gut healing” is not one treatment target.
The limited human bowel research reviewed by FDA used a rectal preparation for ulcerative colitis and did not establish effectiveness. It does not show that capsules relieve IBS or reflux. Knowing which problem you are trying to address is more useful than treating all digestive discomfort as the same condition.
Oral or injected: what changes?
Oral products avoid injections. Injected products add needles, preparation and sterility concerns; both forms still require reliable product contents.
The common rule “oral for gut, injections for injuries” goes further than the human evidence. Even the animal ligament research tested oral as well as injected treatment. No verified human comparison establishes the better route for healing a particular injury.
How long before you notice a difference?
There is no dependable human response time or validated recovery cycle. Reports of feeling better within days are not a deadline for a tendon or ligament to heal.
For an injury, follow progress in the same activities over time: symptoms, movement, strength and tolerance of the rehabilitation load. A less painful day or a falling peptide curve is not clearance to resume full training.
What are the trade-offs?
The decision involves uncertain benefit, incompletely known drug risks and product quality. FDA highlights possible immune reactions and peptide impurities. The two-person IV pilot reported no short-term problems, but was too small to establish side-effect rates or long-term safety.
A purity claim does not prove a product is sterile, and neither proves it will help your injury or gut symptoms.
Model details: BPC-157 · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Relative timing from animal research; a human blood profile is not established.
Timing assumptions and sources
Rat IM 100 microgram/kg saline BPC157: half-life 17.1 min, Tmax 3 min. The 2-person human IV pilot reports safety biomarkers, not peptide concentration calibration.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.285 hours
- Absorption half-life assumed
- 0.009976653 hours
- Reference amount for the relative scale
- 1 mg
- The faster rate is inferred to match the 0.05 h source-scoped peak time; absorption half-life 0.009976653025332967 h is a mathematical shape parameter, not separately measured.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Animal IM timing does not establish human SC absorption or elimination.
- Do not use total radiolabel half-life: the radiolabel includes metabolites and recycled amino acids.
- Rat/dog Cmax must not be scaled into a human blood estimate.
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.
Rat IM 100 microgram/kg saline BPC157: half-life 17.1 min, Tmax 3 min. The 2-person human IV pilot reports safety biomarkers, not peptide concentration calibration.
- He et al.2022, original BPC157 rat/dog PK
Rat IM100 microgram/kg:17.1 min half-life and 3 min Tmax. Human extrapolation deliberately limited to relative timing.
- Lee and Burgess2025, two-person human IV pilot
Safety bloodwork and vital signs; no reported BPC157 plasmaPK endpoints in the abstract.
bpc-157-relative-timing-2026-10 · version 1
Common questions
Should BPC-157 be injected close to the injury?
No human comparison establishes an advantage. The published knee report used injections into the joint in a clinic; it does not show that self-injecting beside a tendon works better, or justify injecting into a painful joint or tendon.
Does adding TB-500 work better than BPC-157 alone?
That has not been demonstrated. Only four people in the small knee report received BPC-157 plus thymosin beta-4, without a controlled comparison. Also, TB-500 can refer to a shorter fragment, so a marketed blend may not match that preparation.
Sources Labels, studies and notes behind this guide
Catalog evidence: Other human research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- What people hope to notice
- Returning to training or ordinary activity is a common goal in recovery discussions.
- Forms people compare
- Oral use avoids needles; injections add preparation and sterility concerns.
- Also compared with
- People ask whether adding it improves recovery. The small human combination report does not settle that.
- 1. Lee and Padgett — human knee-pain report
Retrospective clinic report: 16 people reached by phone; 12 received BPC-157 alone and four BPC-157 plus TB4. No control group, standardized function measures or imaging-confirmed healing; cannot establish added benefit from stacking.
- 2. FDA — BPC-157 scientific review, July 2026
Human UC evidence section: 53-person rectal-enema study available as a meeting abstract, insufficient to establish benefit/safety; no oral or SC UC studies identified. Safety sections distinguish immune/impurity concerns from adverse-event reports whose causality is unclear.
- 3. House of Gaia: treatment brochure, BPC-157 entry
Full PDF opened; BPC-157 entry on PDF page 44 (zero-based 43), under Key Longevity Peptides & Protocols. All three visible fields are on the same BPC-specific line. The brochure sits within a broader multi-peptide longevity program, but this is not a BPC/TB combined-course duration. Its efficacy, rejuvenation and safety claims are not adopted. PDF URL path is May 2025; content reviewed October 7, 2026.
- 4. Staresinic et al. — muscle-injury recovery in rats
Original rat quadriceps-transection study measured tissue repair and function; not a human muscle-growth or training-recovery trial.
- 5. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.
Rat IM 100 microgram/kg saline BPC157: half-life 17.1 min, Tmax 3 min. The 2-person human IV pilot reports safety biomarkers, not peptide concentration calibration.
- 6. He et al.2022, original BPC157 rat/dog PK
Rat IM100 microgram/kg:17.1 min half-life and 3 min Tmax. Human extrapolation deliberately limited to relative timing.
- 7. Lee and Burgess2025, two-person human IV pilot
Safety bloodwork and vital signs; no reported BPC157 plasmaPK endpoints in the abstract.
- 8. Staresinic et al. — Achilles tendon repair in rats
Original animal study; surgically cut Achilles tendons, injected BPC-157, mechanical strength, walking and tissue measures. No human recovery timeline or near-site injection comparison.
- 9. Cerovecki et al. — ligament healing in rats
Original rat MCL study tested oral, abdominal-cavity injection and topical routes. Supports animal repair interest, not a rule that oral use is only for the gut or a human dose.
- 10. Lee and Burgess — two-person IV pilot
Two adults with previous BPC-157 exposure; short monitoring over three days, no reported adverse effects. Does not establish long-term safety, adverse-event rates or an injury/gut regimen.
- 11. Bern consensus on returning to sport after injury
Clinical consensus: return to sport is a multifactorial decision incorporating function, strength, loading and injury-specific rehabilitation. Used only for general recovery interpretation, not a BPC-157 efficacy claim.
- 12. TB-500 fragment identity and metabolism
Original laboratory/rat study defines TB-500 as Ac-LKKTETQ. Full thymosin beta-4 and products marketed as TB-500 are not automatically the same preparation.
Keep reading
Related compounds and examples
Related compounds
TB-500 (Thymosin Beta-4)
Why people research TB-500 for tendon, muscle and joint recovery, how reported courses are described, and what to know when comparing it with BPC-157.
TB-500 Fragment
The TB-500 fragment is a small piece of thymosin beta-4. Researchers study both the fragment and what it breaks down into; these can have different effects in laboratory experiments.
ARA-290 (Cibinetide)
ARA-290 for nerve symptoms: research doses, 28-day studies and realistic expectations for neuropathy.
Protocols featuring BPC-157
Wolverine Stack
Popular healing/repair stack pairing BPC-157 with TB-500 for soft-tissue and recovery support.
Skin GLOW Stack
Comprehensive skin-and-recovery blend (GHK-Cu + TB-500 + BPC-157 + KPV) dosed daily for collagen, healing, and anti-inflammatory support. Based on the GLOW/Upgraded-Glow blend ratios.
BPC-157 + TB-500 Healing Blend
The popular pre-mixed healing blend reconstituted as a protocol: daily BPC-157 with weekly TB-500 for soft-tissue and recovery support.